Cardioprotection thread, page-524

There is a plethora of information around why drugs fail and successful drug repurposing. Indeed even Keytruda was close to being sold off before it was commercialized. Bisantrene story was that its original formulation (RC110) meant a more invasive treatment with a smaller market and for internal reasons post being acquired, Lederle chose between their pipeline oncology drugs and commercialized another. Not that Bisantrene did not work as the studies from the period showed. The new formulation has greater commercial appeal if successful.